导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 4.67% | 1358/4773 |
| 近一周 | -0.74% | 1241/5465 |
| 近一月 | -3.42% | 2484/5421 |
| 近一季 | -7.25% | 2732/5231 |
| 近半年 | -3.76% | 2585/4920 |
| 近一年 | 8.75% | 1284/4394 |
| 近两年 | 66.37% | 1080/2954 |
| 近三年 | 40.87% | 741/2253 |
| 成立以来 | 26.64% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
1.73% 1199/4961 |
16.55% 1554/5312 |
- - |
- - |
| 2025 | 30.42% 1323/4813 |
2.27% 1418/3635 |
3.22% 1101/4076 |
22.79% 1612/4524 |
0.61% 1898/4813 |
| 2024 | 7.51% 1650/3463 |
0.25% 1011/2808 |
-2.10% 1136/3014 |
11.13% 2551/3129 |
-1.43% 1700/3463 |
| 2023 | -5.50% 746/2656 |
5.17% 818/2280 |
-1.75% 525/2385 |
-4.78% 1220/2515 |
-3.95% 827/2655 |
| 2022 | -23.56% 1146/2207 |
-15.00% 1017/1919 |
1.89% 1406/2016 |
-10.99% 482/2113 |
-0.84% 1649/2208 |
| 2021 | 14.39% 335/1822 |
-1.31% 464/1255 |
10.20% 487/1330 |
3.57% 403/1466 |
1.55% 878/1822 |
| 2020 | - - |
- - |
- - |
- - |
- - |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 汇安中证500增强A VS. 长安沪深300非周期A(740101) |